Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD)....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 6 June 2026
2017-03-27 06:33:00 Monday ET

Goldman Sachs chief economist Jan Hatzius says the Federal Reserve's QE exit strategy makes sense ahead of Fed Chair Janet Yellen's stepdown in 2018
2018-06-05 07:36:00 Tuesday ET

Just Capital issues a new report in support of the stakeholder value proposition in recent times. U.S. corporations that perform best on key priorities such
2018-06-25 12:43:00 Monday ET

Apple and Samsung are the archrivals for the title of the world's top smart phone maker. The recent patent lawsuit settlement between Apple and Samsung
2018-12-01 11:37:00 Saturday ET

As the solo author of the books Millionaire Next Door and Richer Than Millionaire, William Danko shares 3 top secrets for *better wealth creation*. True pro
2018-11-23 09:39:00 Friday ET

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma. After the U.S. midterm electio
2019-07-17 12:37:00 Wednesday ET

Gold prices surge above $1400 per ounce amid global trade tension and economic policy uncertainty. Both European Central Bank and Bank of Japan may consider